Block CEO Jack Dorsey outlined the reasons for the job cuts and why they were happening now in an employee letter. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-Day free trial now.

On March 25, a substantial insider purchase was made by John W. Guinee III, Board Member at Plymouth Industrial REIT PLYM, as per the latest SEC filing. What Happened: In a significant move reported in a Form 4 filing with the U.S.

It was reported on March 25, that Randall K Fields, Chief Executive Officer at ReposiTrak TRAK executed a significant insider sell, according to an SEC filing. What Happened: Fields's decision to sell 7,500 shares of ReposiTrak was revealed in a Form 4 filing with the U.S.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Fort Lauderdale, FL, March 26, 2025 ( GLOBE NEWSWIRE ) -- CentralReach, a leading provider of Autism and IDD Care software for ABA, multidisciplinary, and special education, today announced the latest edition of its Autism and IDD Care Market Report.

Fresh Del Monte acquires Avolio to enter avocado oil market. The avocado oil industry is expected to grow at 8%-10% CAGR. Pelosi's latest AI pick skyrocketed 169% in just one month. Click here to discover the next stock our government trade tracker is spotlighting-before it takes off.

Shares of Ford Motor ( F ) are testing an important resistance level. They may be about to breakout and move higher. Pelosi's latest AI pick skyrocketed 169% in just one month. Click here to discover the next stock our government trade tracker is spotlighting-before it takes off.

...

As of March 26, 2025, two stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...

GSK's Blujepa met primary endpoints in phase 3 trials, showing 58.5% success in EAGLE-3 vs. 43.6% for nitrofurantoin in uUTI treatment. The FDA approved Blujepa for uUTIs in female adults and pediatric patients, with a U.S. launch planned for 2H 2025. Pelosi's latest AI pick skyrocketed 169% in ...